Osilodrostat for Cushing syndrome.
出版信息
Aust Prescr. 2025 Apr;48(2):67-68. doi: 10.18773/austprescr.2025.010.
Abstract
摘要
相似文献
1
Osilodrostat for Cushing syndrome.奥西卓司他用于治疗库欣综合征。
Aust Prescr. 2025 Apr;48(2):67-68. doi: 10.18773/austprescr.2025.010.
2
Osilodrostat: A Review of Recent Clinical Studies and Practical Recommendations for its Use in the Treatment of Cushing Disease.奥昔拉定：最近临床研究综述及在库欣病治疗中应用的实用建议。
Endocr Pract. 2021 Sep;27(9):956-965. doi: 10.1016/j.eprac.2021.06.012. Epub 2021 Aug 10.
3
Osilodrostat for Cushing Disease and Its Role in Pediatrics.奥昔拉定治疗库欣病及其在儿科中的作用。
Horm Res Paediatr. 2023;96(6):573-580. doi: 10.1159/000522054. Epub 2022 Jan 19.
4
Efficacy and Safety of Osilodrostat in Paraneoplastic Cushing Syndrome: A Real-World Multicenter Study in France.奥西罗度肽治疗副肿瘤性库欣综合征的疗效和安全性：法国真实世界多中心研究。
J Clin Endocrinol Metab. 2023 May 17;108(6):1475-1487. doi: 10.1210/clinem/dgac691.
5
Osilodrostat Treatment of Cushing Syndrome in Real-World Clinical Practice: Findings From the ILLUSTRATE study.奥西卓司他在真实世界临床实践中治疗库欣综合征：来自ILLUSTRATE研究的结果。
J Endocr Soc. 2025 Mar 15;9(5):bvaf046. doi: 10.1210/jendso/bvaf046. eCollection 2025 May.
6
Successful Management of Cushing Syndrome From Ectopic ACTH Secretion in an Adolescent With Osilodrostat.奥西卓司他成功治疗青少年异位促肾上腺皮质激素分泌所致库欣综合征
JCEM Case Rep. 2023 Aug 17;1(4):luad101. doi: 10.1210/jcemcr/luad101. eCollection 2023 Jul.
7
A Case of Severe Cushing Syndrome due to Metastatic Adrenocortical Carcinoma Treated With Osilodrostat.一例用奥西卓司他治疗的转移性肾上腺皮质癌所致严重库欣综合征病例
AACE Clin Case Rep. 2024 Oct 23;11(1):53-57. doi: 10.1016/j.aace.2024.10.005. eCollection 2025 Jan-Feb.
8
Metyrapone Versus Osilodrostat in the Short-Term Therapy of Endogenous Cushing's Syndrome: Results From a Single Center Cohort Study.美替拉酮与奥曲肽短期治疗内源性库欣综合征的比较：来自单中心队列研究的结果。
Front Endocrinol (Lausanne). 2022 Jun 13;13:903545. doi: 10.3389/fendo.2022.903545. eCollection 2022.
9
Osilodrostat Treatment for Adrenal and Ectopic Cushing Syndrome: Integration of Clinical Studies With Case Presentations.奥西卓司他治疗肾上腺性和异位库欣综合征：临床研究与病例报告的整合
J Endocr Soc. 2025 Feb 14;9(4):bvaf027. doi: 10.1210/jendso/bvaf027. eCollection 2025 Mar 3.
10
Osilodrostat: First Approval.奥昔拉定：美国首次批准
Drugs. 2020 Apr;80(5):495-500. doi: 10.1007/s40265-020-01277-0.
本文引用的文献
1
Cushing's syndrome.库欣综合征
Lancet. 2023 Dec 9;402(10418):2237-2252. doi: 10.1016/S0140-6736(23)01961-X. Epub 2023 Nov 17.
2
Long-term efficacy and safety of osilodrostat in patients with Cushing's disease: results from the LINC 4 study extension.奥昔孕诺特治疗库欣病患者的长期疗效和安全性：LINC 4 研究扩展的结果。
Front Endocrinol (Lausanne). 2023 Aug 23;14:1236465. doi: 10.3389/fendo.2023.1236465. eCollection 2023.
3
Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase.奥昔孕肽治疗库欣病患者的疗效和安全性（LINC 3）：一项多中心 III 期研究，包括双盲、随机撤药阶段。
Lancet Diabetes Endocrinol. 2020 Sep;8(9):748-761. doi: 10.1016/S2213-8587(20)30240-0. Epub 2020 Jul 27.
Zotero 插件